Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.61 |
| ▸ | CCNC | P24863 | 1/20 | 0.60 |
| ▸ | CDK8 | P49336 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 4/20 | 0.58 |
| ▸ | EGFR | P00533 | 2/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174300 | 0.88 | KDR (0.70) | NAMPTCCNCCDK8KDREGFR | |
| SCHEMBL16628034 | 0.86 | MAPT (0.60) | KDRMEN1RAB9AKMT2AMTOR | |
| SCHEMBL11001590 | 0.82 | EPHX2 (0.81) | KDREGFRFGFR1MEN1RAB9A | |
| SCHEMBL939205 | 0.81 | KDR (0.79) | CDK8KDREGFRFGFR1EPHX2 | |
| SCHEMBL16620819 | 0.80 | MAPT (0.59) | KDRMEN1POLBRAB9AKMT2A | |
| SCHEMBL16628073 | 0.80 | CA12 (0.59) | KDREGFRFGFR1MEN1RAB9A | |
| SCHEMBL16628086 | 0.80 | KDR (0.68) | CCNCCDK8KDRMEN1POLB | |
| SCHEMBL4238045 | 0.79 | MEN1 (0.67) | NAMPTCCNCCDK8KDRMEN1 | |
| SCHEMBL17664318 | 0.79 | EPHX2 (0.81) | KDREGFRFGFR1MEN1RAB9A | |
| SCHEMBL2681462 | 0.77 | MAPT (0.78) | KDRMEN1RAB9AKMT2AMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200138829-A1 | METHODS OF CANCER TREATMENT | Ferro Therapeutics, Inc. | 2020-05-07 | — | — | US | disclosed |
| WO-2015051149-A1 | SORAFENIB ANALOGS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051149-A1 | SORAFENIB ANALOGS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138829-A1 | METHODS OF CANCER TREATMENT | AIFM2, GPX4, DDIT3 | NAMPT 388/4885CCNC 2581/4885CDK8 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.